RBM15B Promotes Prostate Cancer Cell Proliferation via PCNA m6A Modification
- PMID: 39361104
- DOI: 10.1007/s12013-024-01558-5
RBM15B Promotes Prostate Cancer Cell Proliferation via PCNA m6A Modification
Abstract
Prostate cancer (PC) is the most frequently occurring cancer in men, characterized by the abnormal proliferation of cells within the prostate gland. This study explores the role of RNA binding motif protein 15B (RBM15B) in PC. RBM15B expression levels in PC patients were predicted using the Starbase database. The expression of RBM15B and proliferating cell nuclear antigen (PCNA) expression in PC cells was detected. Following RBM15B knockdown, cell proliferation assays were conducted. N6-methyladenosine (m6A) levels in PC cells were quantified, and RNA immunoprecipitation was performed to analyze the binding of m6A and YTH N-methyladenosine RNA binding protein 1 (YTHDF1) on PCNA mRNA. The stability of PCNA mRNA was assessed after treatment with actinomycin D. An in vivo nude mouse xenograft model was created to validate the role of RBM15B. The findings revealed the upregulation of RBM15B in PC. RBM15B knockdown resulted in decreased proliferation, colony formation, and EdU-positive cells. Mechanical analysis showed that RBM15B facilitated m6A modification of PCNA mRNA, leading to increasing m6A methylation. YTHDF1 bound to these m6A sites on PCNA mRNA, thus stabilizing it. Furthermore, PCNA overexpression mitigated the effects of RBM15B knockdown on PC cell proliferation. In conclusion, RBM15B promotes PC cell proliferation by enhancing the stability of PCNA mRNA through YTHDF1-mediated m6A modification.
Keywords: Cell proliferation; PCNA; Prostate cancer; RBM15B; m6A.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Compliance with ethical standards. Conflict of interest: The authors declare no competing interests.
Similar articles
-
PSMD14 Transcriptionally Activated by MEF2A Promotes Pancreatic Cancer Development by Upregulating SPON2 Expression.Kaohsiung J Med Sci. 2025 May;41(5):e70007. doi: 10.1002/kjm2.70007. Epub 2025 Mar 11. Kaohsiung J Med Sci. 2025. PMID: 40066751 Free PMC article.
-
RNA N6-methyladenosine-modified-binding protein YTHDF1 promotes prostate cancer progression by regulating androgen function-related gene TRIM68.Eur J Med Res. 2023 Dec 2;28(1):552. doi: 10.1186/s40001-023-01533-5. Eur J Med Res. 2023. PMID: 38042806 Free PMC article.
-
YTHDF1 promotes gallbladder cancer progression via post-transcriptional regulation of the m6A/UHRF1 axis.J Cell Mol Med. 2024 May;28(9):e18328. doi: 10.1111/jcmm.18328. J Cell Mol Med. 2024. PMID: 38683130 Free PMC article.
-
Methylation recognition protein YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) regulates the proliferation, migration and invasion of osteosarcoma by regulating m6A level of CCR4-NOT transcription complex subunit 7 (CNOT7).Bioengineered. 2022 Mar;13(3):5236-5250. doi: 10.1080/21655979.2022.2037381. Bioengineered. 2022. PMID: 35156522 Free PMC article.
-
METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.Mol Cell Biochem. 2024 Jul;479(7):1707-1720. doi: 10.1007/s11010-024-05023-y. Epub 2024 May 31. Mol Cell Biochem. 2024. PMID: 38822192
References
-
- Wasim, S., Lee, S. Y., & Kim, J. (2022). Complexities of Prostate Cancer. Int J Mol Sci, 23(22), 14257. https://doi.org/10.3390/ijms232214257 . - DOI - PubMed - PMC
-
- Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022). Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules, 27(17), 5730. https://doi.org/10.3390/molecules27175730 . - DOI - PubMed - PMC
-
- Evans, A. J. (2018). Treatment effects in prostate cancer. Mod Pathol, 31(S1), S110–S121. https://doi.org/10.1038/modpathol.2017.158 . - DOI - PubMed
-
- Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018). Genetics and biology of prostate cancer. Genes Dev, 32(17-18), 1105–1140. https://doi.org/10.1101/gad.315739.118 . - DOI - PubMed - PMC
-
- Tetreault-Laflamme, A., & Crook, J. (2017). Options for Salvage of Radiation Failures for Prostate Cancer. Semin Radiat Oncol, 27(1), 67–78. https://doi.org/10.1016/j.semradonc.2016.08.007 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous